PF-Atlas › Clinical Trials › NCT05483907
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
BBT-877 · Phase 2
Registry ID
NCT05483907
Phase
Phase 2
Status
Completed
Drug / intervention
BBT-877
Sponsor
Bridge Biotherapeutics, Inc.
Start
2023-04-12
Enrollment
129
Locations
44
About this trial
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05483907 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.